Leap Therapeutics, Inc.
(NASDAQ : LPTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.15%247.721.3%$844.18m
MRNAModerna, Inc. 2.92%69.870.0%$763.28m
NVAXNovavax, Inc. -6.19%108.3696.5%$693.95m
IMMUImmunomedics, Inc. 0.22%85.5311.0%$600.97m
GILDGilead Sciences, Inc. 0.02%65.051.0%$599.14m
REGNRegeneron Pharmaceuticals, Inc. -1.73%555.242.7%$445.10m
BIIBBiogen, Inc. -0.32%274.481.6%$332.97m
VRTXVertex Pharmaceuticals, Inc. -2.24%265.391.9%$329.17m
ILMNIllumina, Inc. -0.85%295.503.5%$313.09m
SRNESorrento Therapeutics, Inc. -0.53%9.431.5%$274.82m
ALXNAlexion Pharmaceuticals, Inc. -0.36%113.722.0%$266.55m
BMRNBioMarin Pharmaceutical, Inc. 1.30%79.384.3%$239.49m
MNTAMomenta Pharmaceuticals, Inc. -0.13%52.263.0%$237.34m
VXRTVaxart, Inc. 3.01%8.220.0%$213.57m
SGENSeattle Genetics, Inc. 3.01%180.946.0%$194.15m

Company Profile

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.